Report: FDA Greenlit Record Diagnostics, Improved PMA Decision Times Despite COVID-19
Executive Summary
Despite industry concerns the US FDA may be significantly falling behind on non-COVID-19 product reviews, analysts at Wells Fargo find that the agency has actually improved in areas such as PMA decision times.